We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is BioCryst Pharmaceuticals (BCRX - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
BioCryst Pharmaceuticals is a member of our Medical group, which includes 987 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BioCryst Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BCRX's full-year earnings has moved 324.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, BCRX has returned 18.9% so far this year. In comparison, Medical companies have returned an average of -3.1%. This shows that BioCryst Pharmaceuticals is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Cardinal Health (CAH - Free Report) . The stock is up 39.5% year-to-date.
The consensus estimate for Cardinal Health's current year EPS has increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, BioCryst Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 155 individual companies and currently sits at #67 in the Zacks Industry Rank. On average, this group has gained an average of 3.5% so far this year, meaning that BCRX is performing better in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 14-stock industry is currently ranked #27. The industry has moved +0.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to BioCryst Pharmaceuticals and Cardinal Health as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is BioCryst Pharmaceuticals (BCRX - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
BioCryst Pharmaceuticals is a member of our Medical group, which includes 987 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BioCryst Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BCRX's full-year earnings has moved 324.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, BCRX has returned 18.9% so far this year. In comparison, Medical companies have returned an average of -3.1%. This shows that BioCryst Pharmaceuticals is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Cardinal Health (CAH - Free Report) . The stock is up 39.5% year-to-date.
The consensus estimate for Cardinal Health's current year EPS has increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, BioCryst Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 155 individual companies and currently sits at #67 in the Zacks Industry Rank. On average, this group has gained an average of 3.5% so far this year, meaning that BCRX is performing better in terms of year-to-date returns.
On the other hand, Cardinal Health belongs to the Medical - Dental Supplies industry. This 14-stock industry is currently ranked #27. The industry has moved +0.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to BioCryst Pharmaceuticals and Cardinal Health as they could maintain their solid performance.